Health

U.S. Food and Drug Administration Updates Camzyos (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications

DailyTrendDailyTrend
Apr 22, 2025 - 13:00
 0  3
U.S. Food and Drug Administration Updates Camzyos (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
PRINCETON, N.J.-- April 17, 2025 -- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

FDA is Requiring Opioid Pain Medicine Manufacturers to Update Prescribing Information Regarding Long-Term Use: Drug Safety Communication

FDA is Requiring Opioid Pain Medicine Manufacturers to ...

DailyTrend Aug 4, 2025  0  0

Trump Announces Health Care Records System for Consumers

Trump Announces Health Care Records System for Consumers

DailyTrend Jul 31, 2025  0  0

New Implant Offers Hope for Easing Rheumatoid Arthritis

New Implant Offers Hope for Easing Rheumatoid Arthritis

DailyTrend Jul 31, 2025  0  0

Radioactive Wasps Found at Nuclear Site in South Carolina Could Be a ‘Red Flag,’ Expert Says

Radioactive Wasps Found at Nuclear Site in South Caroli...

DailyTrend Aug 1, 2025  0  0

US FDA Approves New Biktarvy Indication For People With HIV Who Are Treatment Experienced And Restarting Antiretroviral Treatment

US FDA Approves New Biktarvy Indication For People With...

DailyTrend Aug 2, 2025  0  0

For Some, Return of Presidential Fitness Test Revives Painful Memories

For Some, Return of Presidential Fitness Test Revives P...

DailyTrend Aug 2, 2025  0  0